hero-line-left hero-line-top

Publications

hero-line-bottom
hero-line-horizontal
temp-hero-icon

Considerations for Use of Real-World Evidence in Oncology

Informed by several pilot projects leveraging a common protocol (established in the RWE 1.0 Pilot Project and expanded upon in subsequent pilots, described below) among multiple real-world data partners, US and international populations, and oncology-specific disease settings, Friends of Cancer Research (Friends) and collaborators identified implications of dataset specifics and patient characteristics on real-world endpoints and recommendations for developing a RWE framework to encourage and guide future RWE studies that leverage multiple data sources to answer a single question through a harmonized protocol.

October 2020 | White paper |  Written by Friends of Cancer Research in collaboration with leading real-world evidence organizations

Using Real-World Data (RWD) from an integrated platform for rapid analysis of patients with cancer with and without COVID-19 across distinct health systems

Authors: Gadgeel SM1; Thompson MA2; Izano MA3; Hwang C1; Mikkelsen T1, Weese JL2, Wolf FM3, Schrag A3, Walters S3, Singh H4, Hirsch J3, Brown TD3, Kluetz PG4.

July 2020 | Presented at: AACR Virtual Meeting –– COVID-19 and Cancer

Overall survival in high and very high PD-L1 expressing patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors in a real-world data setting.

Chenan Zhang, Connor Sweetnam, Frank Wolf, Sheetal Walters, Jonathan Hirsch, Thomas D. Brown; Syapse, San Francisco, CA; Syapse Inc., San Francisco, CA; Syapse Inc., San Francisco, CA

May 2020 | Presented at: ASCO Virtual Scientific Program

Outcomes in patients with advanced non-small cell lung cancer (aNSCLC) and high PD-L1 expression treated with immune checkpoint inhibitor monotherapy: An FDA-pooled analysis.

Sujay Yogesh Shah, Jonathon Joseph Vallejo, Yutao Gong, Thomas D. Brown, Chenan Zhang, Jonathan Hirsch, Shenghui Tang, Gideon Michael Blumenthal, Harpreet Singh, Paul Gustav Kluetz, Marc Robert Theoret, Julia A. Beaver, Richard Pazdur; Food & Drug Administration, Silver Spring, MD; U.S. Food and Drug Administration, Silver Spring, MD; Swedish Cancer Institute, Seattle, WA; Syapse, San Francisco, CA; National Cancer Institute at the National Institutes of Health, Bethesda, MD

May 2020 | Presented at: ASCO Virtual Scientific Program

Molecular alterations with hyperprogression in lung cancer patients treated with immune checkpoint inhibitors in a large health system.

Eyob ale Tadesse, Kayla Heslin, Mohamed Hendawi, Jonathan Hirsch, Christopher Idyro, Michael A. Thompson; Advocate Aurora Health, Milwaukee, WI; Syapse, San Francisco, CA; Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI

May 2020 | Presented at: ASCO Virtual Scientific Program

Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration.

Donna R. R Rivera, Laura Lasiter, Jennifer Christian, Lindsey Enewold, Janet L. Espirito, Eric Hansen, Henry J. Henk, Lawrence H. Kushi, Daniel Lane, Yanina Natanzon, Ruth Pe Benito, Erik Rasmussen, Nicholas J. Robert, Mark Stewart, Connor Sweetnam, Olga Tymejczyk, Emily Valice, Joseph Wagner, Alia Zander, Jeff Allen; National Cancer Institute, Rockville, MD; Friends of Cancer Research, Washington, DC; IQVIA, Research Triangle Park, NC; National Cancer Institute, Bethesda, MD; McKesson Life Sciences, The Woodlands, TX; COTA, Inc., New York, NY; OptumLabs, Shakopee, MN; Kaiser Permanente, Oakland, CA; COTA Healthcare, Boston, MA; Syapse, San Francisco, CA; Tempus, Chicago, IL; Flatiron Health, New York, NY; 10101 Woodloch Forest, The Woodlands, TX; Syapse Inc., San Francisco, CA; Kaiser Permanente Division of Research, Oakland, CA; IQVIA, Plymouth Meeting, PA

May 2020 | Presented at: ASCO Virtual Scientific Program

Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data.

Lawrence H. Kushi, Laura Lasiter, Andrew J. Belli, Marley Boyd, Suanna S. Bruinooge, Jennifer Christian, Elizabeth Garrett-Mayer, Eric Hansen, Rebecca Honnold, Ruth Pe Benito, Yanina Natanzon, Lori Sakoda, Donna R. R Rivera, Whitney Rhodes, Nicholas J. Robert, Elad Sharon, Connor Sweetnam, Joseph Wagner, Mark S. Walker, Jeff Allen; Kaiser Permanente, Oakland, CA; Friends of Cancer Research, Washington, DC; COTA, Inc., New York, NY; McKesson Life Sciences, The Woodlands, TX; American Society of Clinical Oncology, Alexandria, VA; IQVIA, Research Triangle Park, NC; Tempus Labs, Chicago; Tempus, Chicago, IL; Syapse, San Francisco, CA; Kaiser Permanente Northern California, Division of Research, Oakland, CA; National Cancer Institute, Rockville, MD; Concerto HealthAI, Memphis, TN; 10101 Woodloch Forest, The Woodlands, TX; National Cancer Institute, Bethesda, MD; Syapse Inc., San Francisco, CA; IQVIA, Plymouth Meeting, PA; ACORN Research LLC, Memphis, TN

May 2020 | Presented at: ASCO Virtual Scientific Program

Pneumonitis incidence in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy in clinical trials and real-world data

Qi Liu, Chenan Zhang, Yutao Gong, Hao Zhu, Elaine Chang, Cheryl Cho-Phan, Jonathan Hirsch, Michael A. Thompson, Gideon Blumenthal, Shiew Mei Huang, Thomas D. Brown.

April 2020 | Presented at: AACR Annual Meeting